Evidence map›Paper›PMID 41549307›Full record

ArticleCardiovascular diabetology2026

Association between the newly proposed triglyceride glucose-a body shape index (TyG-ABSI) and atherosclerotic cardiovascular disease in the general population: modest diagnostic improvement compared with traditional TyG-related parameters.

Jiajun Qiu, Jin'e Li, Shan Xu, Lixuan Fang, Yang Zou, Hongtao Zhou, Jiaying Feng, Yujie Zan, Yu Lu, Ying Zhou and 1 more

Abstract readComparative Study
In one paragraph

Article in Cardiovascular diabetology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jiajun Qiu *Department of Endocrinology and Metabolism of the Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 1, Minde Road, Nanchang, 330006, Jiangxi, China.
Jin'e Li *Department of Endocrinology and Metabolism of the Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 1, Minde Road, Nanchang, 330006, Jiangxi, China.
Shan Xu *Department of Endocrinology and Metabolism of the Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 1, Minde Road, Nanchang, 330006, Jiangxi, China.
Lixuan FangDepartment of Endocrinology and Metabolism of the Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 1, Minde Road, Nanchang, 330006, Jiangxi, China.
Yang ZouJiangxi Cardiovascular Research Institute, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, Jiangxi Province, China.
Hongtao ZhouDepartment of Endocrinology and Metabolism of the Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 1, Minde Road, Nanchang, 330006, Jiangxi, China.
Jiaying FengDepartment of Endocrinology and Metabolism of the Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 1, Minde Road, Nanchang, 330006, Jiangxi, China.
Yujie ZanDepartment of Endocrinology and Metabolism of the Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 1, Minde Road, Nanchang, 330006, Jiangxi, China.
Yu LuDepartment of Endocrinology and Metabolism of the Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 1, Minde Road, Nanchang, 330006, Jiangxi, China.
Ying ZhouDepartment of Endocrinology and Metabolism of the Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 1, Minde Road, Nanchang, 330006, Jiangxi, China.
Jianping LiuDepartment of Endocrinology and Metabolism of the Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 1, Minde Road, Nanchang, 330006, Jiangxi, China. ndefy14105@ncu.edu.cn.

Funding

Jiangxi Province Key Laboratory of Molecular Medicine 2024SSY06231Key Research, Development Program of Jiangxi Province 20243BBI91008National Natural Science Foundation of China 82160162Project of the Second Affiliated Hospital of Nanchang University 2022efyA04
6 · The paper itself

Abstract

backgroundAtherosclerotic cardiovascular disease (ASCVD) is a leading global cause of mortality, and reliable risk assessment tools are critical for prevention. While TyG-related parameters are used for ASCVD risk stratification, the association between the novel TyG-ABSI and ASCVD in the general population requires further characterization, and its potential improvement in discrimination over traditional TyG parameters has not been fully elucidated.

methodsWe analyzed data from the National Health and Nutrition Examination Survey (NHANES, 1999–2018), a nationally representative cross-sectional study including 22,466 participants. ASCVD was defined by self-reported physician diagnosis of coronary heart disease (CHD), angina pectoris (AP), myocardial infarction (MI), or stroke. TyG-ABSI and traditional TyG parameters were calculated using standardized laboratory and anthropometric data. Statistical analyses included weighted logistic regression (to assess associations), restricted cubic spline analysis (to explore dose–response relationships), subgroup analyses (to test effect modification), receiver operating characteristic (ROC) curves (to evaluate discrimination ability), and net reclassification improvement (NRI) and integrated discrimination improvement (IDI) (to quantify improvement in reclassification and risk separation). Sensitivity analyses were conducted to verify robustness.

resultsIn fully adjusted models, TyG-ABSI was significantly associated with ASCVD (odds ratio [OR] per standard deviation [SD] increase: 1.15, 95% confidence interval [CI]: 1.09–1.22) and its subtypes (CHD: OR = 1.14, 95%CI: 1.05–1.24; AP: OR = 1.10, 95%CI: 1.01–1.21; MI: OR = 1.15, 95%CI: 1.06–1.25), with a significant linear dose–response relationship observed for ASCVD and all subtypes (all p-trend < 0.05). TyG-ABSI yielded the highest ROC area under the curve (AUC) across all outcomes (ASCVD: 0.69; CHD: 0.70; AP: 0.69; MI: 0.70; stroke: 0.65). Furthermore, TyG-ABSI demonstrated modest but significant improvement in discrimination over traditional TyG parameters for both ASCVD and its subtypes, as evidenced by significant NRI and IDI metrics. Specifically for ASCVD, it correctly reclassified an additional 7.88% (vs TyG-WHtR) to 16.36% (vs TyG-BMI) of patients based on NRI. The association between TyG-ABSI and ASCVD was robust across demographic, lifestyle, and clinical subgroups, as well as in sensitivity analyses.

conclusionThis study indicates a significant positive correlation between TyG-ABSI and ASCVD in the general population. Moreover, TyG-ABSI demonstrates modest improvement in discrimination compared to traditional TyG parameters, identifying additional high-risk individuals via reclassification. These findings suggest that TyG-ABSI holds promise as a candidate marker for optimizing ASCVD risk stratification in clinical practice, though future prospective validation is warranted.

Indexed as

AnthropometryAtherosclerosisBlood GlucoseTriglyceridesAdultAgedBiomarkersCross-Sectional StudiesFemaleHeart Disease Risk FactorsHumansMaleMiddle AgedNutrition SurveysPredictive Value of TestsPrognosisBiomarkersBlood GlucoseTriglyceridesAtherosclerotic cardiovascular diseaseIncremental valueInsulin resistanceTyG-ABSITyG index

Identifiers

PMID41549307
PMCPMC12895803

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.